Preferences on advance care planning and end-of-life care in patients hospitalized for heart failure

Hiroki Kitakata¹, Takashi Kohno¹-²*, Shun Kohsaka¹, Daisuke Fujisawa³, Naomi Nakano¹, Yasuyuki Shiraishi¹, Yoshinori Katsumata⁴, Yuji Nagatomo⁵, Shinsuke Yuasa¹ and Keichi Fukuda¹

¹Department of Cardiology, Keio University School of Medicine, Tokyo, Japan; ²Department of Cardiovascular Medicine, Kyorin University Faculty of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, Japan; ³Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; ⁴Institute for Integrated Sports Medicine, Keio University, Tokyo, Japan; ⁵Department of Cardiology, National Defense Medical College, Saitama, Japan

Abstract

Aims Early engagement in advance care planning (ACP) is recommended in heart failure (HF) management. We investigated the preferences of patients with HF regarding ACP and end-of-life (EOL) care, including their desired timing of ACP initiation.

Methods and results Data were collected using a 92-item questionnaire survey, which was directly distributed to hospitalized patients by dedicated physicians and nurses in a university hospital setting. One-hundred eighty-seven patients agreed to participate (response rate: 92.6%), and 171 completed the survey [valid response rate: 84.7%; men: 67.3%; median age: 73.0 (63.0–81.0) years]. Logistic regression analyses were conducted to identify the predictors of positive attitudes towards ACP. Most recognized ACP as important for their care (n = 127, 74.3%), 48.1% stated that ACP should be initiated after repeated HF hospitalizations in the past year, and 29.0% preferred ACP to begin during the first or second HF hospitalization. Only 21.7% of patients had previously engaged in ACP conversations during HF management. Positive attitudes towards ACP were associated with lower depressive symptoms [two-item Patient Health Questionnaire; odds ratio (OR): 0.75, 95% confidence interval (CI): 0.61–0.92, P-value: 0.006], marriage (OR: 2.53, 95% CI: 1.25–5.12, P-value: 0.010), and a high educational level (OR: 2.66, 95% CI: 1.28–5.56, P-value: 0.009), but not with severity of HF (represented by Seattle Heart Failure Model risk score). Regarding EOL care, while ‘Saying what one wants to tell loved ones’ (83.4%), ‘Dying a natural death’ (81.8%), and ‘Being able to stay at one’s favorite place’ (75.6%) were the three most important factors for patients, preferences for ‘Receiving sufficient treatment’ (56.5%) and ‘Knowing what to expect about future condition’ (50.3%) were divergent.

Conclusions Despite patients’ preferences for ACP conversations, there was a discrepancy between preference and engagement in ACP among patients hospitalized for HF. Patients’ preferences regarding EOL care may differ; physicians need to consider the appropriate ACP approach to align with patients’ care goals.

Keywords Heart failure; Patient preference; Advanced care planning; End-of-life care

Received: 28 January 2021; Revised: 7 July 2021; Accepted: 11 August 2021
*Correspondence to: Takashi Kohno, Department of Cardiovascular Medicine, Kyorin University Faculty of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, Japan. Tel: +81-422-47-5511; Fax: +81-422-44-4137. Email: kohno-ta@ks.kyorin-u.ac.jp

Introduction

Heart failure (HF) is a leading cause of cardiovascular morbidity and mortality.¹ In parallel with new developments in treatment, there is growing recognition of the importance of palliative care in HF management.² Advance care planning (ACP), one of the core domains of primary palliative care, involves prospective identification of a surrogate decision maker and consideration of the type of care patients would prefer, as well as their values and goals, in the event they lose decision-making capacity.³ ACP has been proven effective in improving both patient and caregiver outcomes, including better quality of life, increased concordance between preferred and received care, and decreased rehospitalization at the end of life (EOL).⁴,⁵ As HF has an unpredictable trajectory, timely ACP conducted when the patient is able to participate in the decision-making process should be standard in HF care.⁶ Current clinical guidelines and statements for HF management recommend that cardiologists engage in ACP conversations with their patients throughout the illness course.⁷,⁸
However, despite these recommendations, ACP among HF patients is performed poorly or not at all.9–11 A multisite communication intervention trial for advanced HF found a low rate (17%) of care goal discussions being conducted among patients.9 This indicates an important modifiable gap in optimal HF patient care. Although each hospitalization is an opportunity to discuss ACP,12 patient readiness to engage in ACP should also be considered.8,13 Thus, determining whether hospitalized HF patients really want to discuss ACP, and if so, deciding the most appropriate timing for patients to initiate this discussion, could be the first step in promoting integration of ACP conversations into routine clinical practice. Furthermore, patients’ values and care preferences should be explored prior to conducting ACP.3 Understanding patients’ perspectives towards EOL care is especially critical for effective ACP conversations13; however, little is known about HF patients’ perspectives towards ACP and EOL care.

Thus, to close these knowledge gaps, we aimed to elucidate the following: (i) patients’ preferences for and actual performance of ACP conversations, (ii) the determinants of positive patient attitudes towards ACP conversation, and (iii) the EOL care preferences of patients hospitalized for HF.

Material and methods

Study population

This was a cross-sectional observational study. Participants were consecutively recruited from hospitalized acute HF patients who completed our questionnaire between September 2017 and March 2020 at a single university hospital centre (Keio University Hospital, Tokyo, Japan). On the basis of the Framingham criteria, acute HF was defined as rapid-onset HF or a change in the signs and symptoms of HF that required urgent therapy and hospitalization.14,15 Patients presenting with acute coronary syndrome were excluded from this study.

All patients provided informed consent to participate. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the appropriate institutional review board prior to data collection.

Socio-demographic and clinical variables

Patients’ clinical variables were obtained from their electronic medical records and defined according to the West Tokyo Heart Failure Registry, an ongoing prospective multicentre cohort registry of hospitalized HF patients in Japan.15–17 We collected data on patients’ co-morbidities, aetiology of HF, previous hospital admission for HF, ejection fraction of echocardiography, use of implantable cardioverter defibrillator or cardiac resynchronization therapy, medication use at discharge, and laboratory results from close to discharge or at the time of discharge.

Procedure

After patients’ HF symptoms were stabilized, our multidisciplinary HF team conducted a patient educational programme using written materials for HF instruction guidance (e.g. knowledge about HF, the importance of self-care, and ACP concept) followed by face-to-face counselling by a nurse. After participation in the programme, the patients were given discharge instructions, and the investigators (H. K., T. K., and N. N.) further explained ACP to them. Additionally, while distributing the survey questionnaire, we explained that the items on the questionnaire included ACP and EOL care preferences. In Japan, owing to the universal health coverage system, the mean length of hospital stay among HF patients is substantially longer than in Western countries.15,16 Hence, patients were afforded time to respond to our detailed survey questionnaire after receiving their discharge instructions. Furthermore, when necessary, the patients were assisted with completing the questionnaire, and the items they did not desire to answer were left unanswered.

Survey questionnaire

The survey questionnaire included 92 questions,18 comprising eight domains: (i) patient characteristics (socio-demographic factors including education history, living status, social support, and self-care behaviour); (ii) health status (quality of life and depression); (iii) awareness of HF trajectory; (iv) perspectives on treatment goal; (v) decision-making style; (vi) prognostic understanding and preferences for information disclosure; (vii) emergency treatment preferences; and (viii) ACP and EOL care preferences. In the present study, domains (i), (ii), and (viii) were analysed. For the health status domain, the enrolled HF patients were evaluated for quality of life using the Three-Level EuroQol Five Dimensions (EQ-5D),19 and for depression status using the validated Japanese Patient Health Questionnaire-2 (PHQ-2).20,21

For the ACP preferences domain (Table 1), patients were asked to rate the extent to which they felt it important to choose a surrogate decision maker in the event they could not make their own treatment decisions, complete advance directives (ADs; i.e. document by which patients make provisions for EOL healthcare decisions), and take part in ACP conversation (i.e. talking with family members and healthcare providers about patients preferences regarding their future health care in cases where patients have diminished decision-making capacity) on a 7-point Likert scale (1, absolutely disagree; 2, disagree; 3, somewhat disagree; 4, unsure; 5, somewhat agree; 6, agree; and 7, absolutely agree).
Patients who scored 5 or more for each item were asked whether they had actually established a surrogate decision maker, completed their ADs, and engaged in ACP conversations stratified by presence of previous HF hospitalization, HF severity [Seattle Heart Failure Model (SHFM)-predicted 1 year survival rate and New York Heart Association functional classification], and age were performed. The definitions of ACP and ADs were based on the statement for treatment of elderly HF patients presented by the Japanese Heart Failure Society.22

For the EOL care preferences domain (Table 2), questionnaires comprised nine components adopted from the Good Death Inventory (GDI), an established self-administered questionnaire focusing on bereaved caregivers’ perspectives that has been widely used in EOL care for cancer. This material was produced by collecting responses towards 70 potential attributes of a good death, which were generated based on previous works.23–26 The Japanese concept of a good death constitutes 10 core domains that, in qualitative studies, most Japanese individuals consistently rated as important, and 8 optional domains that were not as consistently rated as important. Thus, the short version of the GDI consists of 18 representative items from each domain, the validity and reliability of which have been confirmed.27 In order to explore EOL preferences that could differ among patients, we selected all eight optional domain items and one core domain item (‘Being able to stay at one’s favorite place’), which were modified to be presented from the patient’s perspective. In the context of a hypothetical EOL setting, patients were asked to respond to each item on a 7-point Likert scale (1, absolutely disagree; 2, disagree; 3, somewhat disagree; 4, unsure; 5, somewhat agree; 6, agree; and 7, absolutely agree). Further, for patients who indicated a preference for ‘Being able to stay at one’s favorite place’, another question regarding specific favourite places during EOL was also added: ‘Where do you think you would like to be for your EOL care?’ (1, home; 2, hospital; 3, nursing facility; and 4, other).

Table 1 Questionnaire for hospitalized heart failure patients

| Questions                                                                 |
|---------------------------------------------------------------------------|
| **1. Preferences for advance care planning**                              |
|                            In patients with advanced HF, decision-making capacity could diminish. How would you rate the importance of these items to you? |
| 1-A. Talking with family members and healthcare providers about your preferences regarding your future healthcare, in the event your decision-making capacity is diminished: |
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
| If you answered ‘somewhat agree’, ‘agree’, or ‘absolutely agree’, have you talked with your family and healthcare providers? |
| 1. Performed 2. Not performed |
| **1-B. Designation of a surrogate decision-maker in cases where your decision-making capacity is diminished:** |
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
| If you answered ‘somewhat agree’, ‘agree’, or ‘absolutely agree’, have you determined a surrogate decision-maker? |
| 1. Determined 2. Not determined |
| **1-C. Document by which you make provision for healthcare decision during your end-of-life care** |
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
| If you answered ‘somewhat agree’, ‘agree’, or ‘absolutely agree’, have you completed this document? |
| 1. Completed 2. Not completed |
| **2. Preferences for end-of-life care**                                    |
| How would you rate the importance of these factors during the end-of-life period? |
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
| Receiving sufficient treatment |
| Dying a natural death |
| Saying what one wants to tell loved ones |
| Knowing what to expect about future condition |
| Dying without awareness that one is dying |
| Not exposing one’s physical and mental weakness to family |
| Feeling that life is worth living |
| Supported by religion |
| Being able to stay at one’s favorite place |
| If you rated being able to stay at one’s favorite place as ‘somewhat agree’, ‘agree’, or ‘absolutely agree’, where do you think you would like to be for your end-of-life care? |
| 1. Home 2. Hospital 3. Nursing facility 4. Other |

HF, heart failure.
Patient recruitment

Among the 342 HF patients admitted at our university hospital, which is an advanced tertiary medical institution, we excluded patients who could not complete the questionnaires (e.g. unconsciousness, n = 9, 2.6%; severe cognitive impairment, n = 79, 23.1%; mental health disorder, n = 14, 4.1%; and language barrier, n = 4, 1.2%), had other end-stage life-threatening diseases (n = 7, 2.0%), or died while hospitalized (n = 15, 4.4%). Furthermore, for patients who were admitted to our hospital more than once and completed repetitive surveys during the study period, those subsequent surveys were excluded (n = 12, 3.5%). Consequently, a total of 202 patients were approached by our questionnaire survey. Among them, 15 patients refused to answer the questionnaire. In addition, nine patients who were unable to answer the questionnaire owing to early discharge and seven patients who did not respond to the question regarding ACP and EOL care preferences were excluded. In total, 171 patients were enrolled in this study.

Statistical analysis

Continuous variables were expressed as means ± standard deviations or a median with an inter-quartile range (IQR), which were dependent on distribution characteristics. Categorical variables were expressed as numbers (percentages). Regarding ACP and EOL care preferences, patients were divided into those with positive attitudes (somewhat agree, agree, and absolutely agree) and those with negative attitudes (absolutely disagree, disagree, somewhat disagree, and unsure) towards each item. Overall, missing data were rarely observed (<5%), with the exception of the percentage of lymphocytes (10.5%). Laboratory values were imputed as median values. Data with missing responses to the questionnaire were eliminated from the analysis. To predict the 1 year survival rate, the SHFM scores were calculated in accordance with the statistical model validating the use of the SHFM in Japanese hospitalized HF patients. Univariable logistic regression analyses were conducted to elucidate the determinants of a positive attitude towards ACP conversation in HF patients. For all statistical analyses, significance was defined as P < 0.05. Graphical data were created using GraphPad Prism 8. Data were analysed using SPSS Version 26 (IBM Corp., Armonk, NY, USA).

Results

Patient clinical characteristics

Participants’ demographic data are shown in Table 2. Enrolled patients were all Japanese and predominantly men (67.3%), with a median age of 73.0 (IQR: 63.0–81.0) years.
and median left ventricular ejection fraction of 44.1% (IQR: 31.3–59.5%). Of these, 84 patients (49.1%) had a history of HF hospitalization. Median SHFM-estimated 1 year survival rate was 94.2 (90.9–96.3).

**Patient preferences for and actual performance of advance care planning**

*Figure 1* presents the questionnaire results regarding patients’ preferences for and the actual performance of ACP conversations. Among 171 respondents, 127 (74.3%) recognized the importance of discussing ACP. Notably, only 21.7% of patients with positive attitudes towards ACP previously had an actual ACP conversation during their HF management (*Figure 1A*). Among the patients with positive attitudes towards ACP, 48.1% thought the discussion should be initiated after repeated hospitalizations for HF in the past year, and 29.0% responded with during the first or second HF hospitalization (*Figure 1B*). Only 17.6% of patients thought that ACP conversations should not be initiated until the terminal disease phase. Among 16 patients with positive attitude towards the initiation of ACP conversation during the first HF hospitalization, only four patients (25.0%) had performed ACP conversation. Among 11 patients who had both previous HF hospitalization and positive attitude towards the initiation of ACP conversation during the second HF hospitalization, three patients (27.3%) actually performed ACP conversation. Regardless of whether patients had been admitted to the hospital for HF prior to their current hospitalization, >70% of patients had positive attitudes towards ACP, of which ~20–25% reported previously having an actual ACP conversation (Supporting Information, *Figure S1A*). Stratification by HF severity and age also demonstrated that most patients (73–77%) recognized ACP as important for their care; however, 17–30% had previously engaged in ACP conversations (Supporting Information, *Figure S1B–S1D*). Further analysis concerning ACP preference among five groups according to age (≤49, 50–59, 60–69, 70–79, and ≥80 years) demonstrated that participants’ preferences did not differ among different age groups (*P* = 0.235; Supporting Information, *Figure S2*).

Supporting Information, *Figure S3* shows patients’ perspective towards designating a surrogate decision maker. Approximately 70% of respondents answered that determining a surrogate decision maker in advance was important, among which 69.5% had actually done so. Regarding patients’ perspectives towards ADs, 53.8% considered ADs to be important, while only 4.9% of patients completed ADs.

**Determinants of positive attitudes towards advance care planning conversation**

Univariate logistic regression analyses showed that lower PHQ-2 scores [odds ratio (OR) 0.75, 95% confidence interval (CI) 0.61–0.92], marriage (OR 2.53; 95% CI 1.25–5.12), and a high educational level (OR 2.66; 95% CI 1.28–5.56) were associated with positive attitudes towards ACP conversation;

---

*Figure 1* Patients’ preferences and engagement in advance care planning (ACP) conversations. (A) The proportions of patients’ preferences and actual performance of ACP conversations in patients hospitalized for heart failure. (B) The proportion of patient-expected optimal timing for ACP initiation among patients with positive attitudes towards ACP conversation. (C) Relationship between Seattle Heart Failure Model (SHFM)-predicted 1 year survival rate and attitudes towards ACP conversation. Bar denotes medians, boxes denote inter-quartile ranges, and whiskers extend to 1.5 inter-quartile range. Dots represent each patient’s 1 year survival rate.
however, previous history of HF hospitalization and SHFM risk scores were not (Table 3). SHFM-estimated 1 year survival rates did not differ between patients with and without positive attitudes towards ACP (Figure 1C).

**Important factors during end-of-life care in advanced heart failure**

*Figure 2* shows the questionnaire results regarding factors perceived as important during their EOL in advanced HF. The Top 3 items identified were ‘Saying what one wants to tell loved ones’ (83.4%), ‘Dying a natural death’ (81.8%), and ‘Being able to stay at one’s favorite place’ (75.6%). In contrast, patients’ preferences were divergent for ‘Receiving sufficient treatment’ (56.5%), ‘Knowing what to expect about future condition’ (50.3%), and ‘Not exposing one’s physical and mental weakness to family’ (44.7%). Those who considered being ‘Supported by religion’ as an important factor accounted for <20%.

Supporting Information, *Figure S4* shows the proportion of patients with positive attitudes towards ACP among those with positive attitudes towards each EOL component. Interestingly, a large proportion of patients with positive attitudes towards each EOL component also considered ACP conversations to be important. Particularly, among patients with positive attitudes towards ‘Knowing what to expect about future condition’ and ‘Supported by religion’, who accounted for <55% of the total cohort, >85% showed positive attitudes towards ACP.

**Discussion**

The present study demonstrated the following key points: (i) though most HF inpatients considered ACP conversations to be important, few actually conducted them; (ii) having a positive attitude towards ACP conversation was associated with lower depression and higher educational levels, but not with estimated prognosis; and (iii) ‘Saying what one wants to tell loved ones’, ‘Dying a natural death’, and ‘Being able to stay at one’s favorite place’ were the most important factors for EOL, although patients’ preferences towards ‘Receiving sufficient treatment’ and ‘Knowing what to expect about future condition’ varied.

To our knowledge, this was the first study to use a hospitalized HF patient cohort to investigate the preferred and actual engagement in ACP conversations. In our cohort, there was a contradiction between patients’ preferences for ACP and its actual performance, which is consistent with previous studies of patients with other medical conditions.28,29 A survey of oncology outpatients in two Australian cancer treatment centres revealed that most respondents considered discussing ACP to be important; however, uptake rates were relatively low.28 A meta-analysis targeting palliative care for adult patients with congenital heart disease revealed that only 1–28% had actually participated in ACP discussions, despite their strong preference towards ACP.29 The willingness of many patients to engage in ACP conversations, including patients with HF,

### Table 3  Determinants of those who considered ‘ACP conversation was important’ among patients’ characteristics

| Variables                                           | OR     | 95% CI       | P-value |
|-----------------------------------------------------|--------|--------------|---------|
| Age (per each year increase)                        | 1.00   | 0.97–1.03    | 0.890   |
| Male                                                | 0.94   | 0.45–1.97    | 0.879   |
| Hypertension                                        | 1.19   | 0.60–2.36    | 0.620   |
| Dyslipidaemia                                       | 1.17   | 0.58–2.39    | 0.657   |
| Diabetes mellitus                                   | 1.60   | 0.77–3.35    | 0.212   |
| Atrial fibrillation                                 | 1.12   | 0.55–2.28    | 0.763   |
| Chronic obstructive pulmonary disease               | 3.93   | 0.88–17.53   | 0.073   |
| History of stroke                                   | 0.93   | 0.36–2.39    | 0.880   |
| History of cancer                                   | 0.71   | 0.33–1.52    | 0.374   |
| Previous heart failure admission                    | 0.95   | 0.48–1.89    | 0.893   |
| LVSF (per each % increase)                          | 1.01   | 0.99–1.03    | 0.388   |
| NYHA III and IV                                     | 1.14   | 0.54–2.40    | 0.736   |
| BNP (per each pg/mL increase)                       | 1.00   | 1.00–1.00    | 0.882   |
| SHFM-estimated 1 year survival rate (per each % increase) | 0.97   | 0.92–1.03    | 0.358   |
| Quality of life (per each EQ-5D score increase)     | 4.40   | 0.64–30.12   | 0.131   |
| Depression (per each PHQ-2 score increase)          | 0.75   | 0.61–0.92    | 0.006   |
| University education or more                        | 2.66   | 1.28–5.56    | 0.009   |
| Married                                             | 2.53   | 1.25–5.12    | 0.010   |
| Having children                                     | 1.97   | 0.91–4.27    | 0.086   |
| Living alone                                        | 0.58   | 0.27–1.24    | 0.160   |

ACP, advance care planning; BNP, brain natriuretic peptide; CI, confidence interval; EQ-5D, EuroQol Five Dimensions; LVSF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification; OR, odds ratio; PHQ-2, Patient Health Questionnaire-2; SHFM, Seattle Heart Failure Model.
suggests a universal gap in current ACP practice. In our study, the majority of patients had positive attitudes towards designating a surrogate decision maker, and many had actually done so. Identifying surrogate decision makers is the first step in shared decision making and ACP. As most HF patients demonstrated positive attitudes towards ACP, physicians should support these patients and their surrogate decision makers to allow for more profound communication regarding patients’ goals, values, and treatment preferences, which could close the gap between patients’ preferences and actual engagement in ACP conversations. As mortality risk increases with each subsequent hospitalization, hospital discharge planning is an opportunity for ACP conversations. Notably, ~70% of HF inpatients in our study considered that the optimal time to initiate ACP conversations was the second admission or repeated admissions for HF in the past year. As ACP requires time and emotional energy, these discussions are often deferred until more urgent and less favourable occasions, leading to impaired decision making. ACP without patient’s readiness does more harm than good; however, the implementation of ACP led to an improvement in patients’ depression and higher satisfaction with the quality of EOL care. Current scientific statement from the American Heart Association recommends that event-driven ‘milestones’ (e.g. worsening HF prompting hospitalization or initiation of intravenous inotropic support) should trigger ACP conversations. Although determining the appropriate timing of these conversations is a formidable challenge, its timing could be comprehensively determined by HF severity as well as patients’ preferences regarding these conversations. It may be necessary to promote early ACP conversations with a multidisciplinary approach during routine care for hospitalized patients with positive attitudes towards its early initiation. This will facilitate shared decision making regarding complex therapeutic options and palliative care that aligns with patients’ personal values.

Patients, families, and healthcare providers could have different perspectives regarding what factors are important at the EOL; therefore, sharing patients’ perspectives on EOL is integral to successfully improving the care of terminal patients. A strength of our study was that we identified HF inpatients’ perspectives towards EOL care, using a questionnaire based on the GDI, consisting of potential attributes Japanese individuals may feel necessary for a good death. Our findings have several clinical implications. First, healthcare providers should know that HF inpatients expect to have communications with people close to them, be in their preferred surroundings, and feel that their life was worth living, which is consistent with findings on other diseases, such as cancer and chronic obstructive pulmonary disease. Second, HF patients’ preferences during EOL varied regarding ‘Dying without awareness that one is dying’. Thus, despite international recommendations for prognostic communications for HF patients, cardiologists should pay attention to the delicate balance between patients’ preference towards ‘Knowing what to expect about future condition’ and towards ‘Dying without awareness that one is dying’. Third, although ~80% patients preferred a natural death, preferences regarding ‘Receiving sufficient treatment’ during EOL varied. For patients with positive preferences for both factors, ACP conversation is mandatory to ensure that patients receive care that is in line with their preferences (e.g. natural death and sufficient treatment from the perspective of individual patients). Fourth, although...
understanding patients’ goals and values remains challenging, hospitalized HF patients could use our questionnaire to express the factors they find important for EOL care. Given that there is considerable variability in EOL preferences,\textsuperscript{36} we believe that patients’ preferences and values should be regularly assessed. To reflect patients’ preferences and goals, educational and training programmes for medical professionals that facilitate specialized knowledge and skills concerning ACP and EOL care are essential.\textsuperscript{37} The importance of these issues has been emphasized in EOL care, especially in recent years.\textsuperscript{37–39}

**Limitations**

There were some limitations to the present study that should be considered when interpreting the results. First, this study was conducted in a single centre with a small number of patients; consequently, statistical power may not have been sufficient to detect any negative outcomes. Second, the study’s cross-sectional design limits our ability to clarify changes, if any, in patients’ attitudes or preferences towards ACP hereafter. Notably, patients can revise their preferences based on changes to their health condition\textsuperscript{36}; further studies will be needed to evaluate changes in attitudes and preference towards ACP and EOL care. Third, we did not investigate patients’ personality traits or wishes for specific treatment or care (e.g. palliation of symptoms or implantable cardioverter defibrillator deactivations). Questions regarding with whom (among medical providers) patients would desire to discuss ACP were not included. In addition, our study’s design hindered us from quantitatively assessing the effect of this survey on the patients’ psychological disturbances, using the validated questionnaires (i.e. PHQ-2). Fourth, our findings might be unique to Japan, where the penetration of and attitudes towards the concept of ACP is significantly different than in Western countries.\textsuperscript{11} Because HF is an international health-related problem, further studies with international collaboration are needed to reassess our findings across different religions and cultural contexts. However, our study demonstrated patients’ positive attitudes and preferences towards engaging in ACP conversations and that hospitalized HF patients preferred these discussions to be initiated in the early disease stage; these findings cast new light on the controversial topic of at what point ACP conversations should be initiated.

**Conclusions**

In conclusion, the majority of patients in the present study considered ACP to be essential and preferred ACP conversations to be initiated during the early stage, rather than the end stage, during the HF trajectory. As patients’ preferences regarding EOL care can differ, physicians need to consider the appropriate approach to ACP, including the timing of initiation, for hospitalized patients with HF.

**Conflict of interest**

S.K. reports investigator-initiated grant funding from Bayer and Daiichi Sankyo. Y.S. is affiliated with an endowed department by Nippon Shinyaku Co., Ltd., and received a research grant from the SECOM Science and Technology Foundation and an honorarium from Otsuka Pharmaceutical Co., Ltd.

**Funding**

This study was supported by Grant-in-Aid for Young Scientists [Japan Society for the Promotion of Science (JSPS) KAKENHI, 18K15860 (Y.S.)], Grants-in-Aid for Scientific Research [17K09526 and 20K08408 (T.K.)], Health Labor Sciences Research Grant by the Ministry of Health, Labour and Welfare [14528506 (S.K.)], and Grant from the Japan Agency for Medical Research and Development [201439013C (S.K.)].

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Figure S1.** Patients’ preferences and engagement in ACP conversations in various subgroups categorized according to the presence of previous HF admission (A), SHFM-predicted one-year survival rate (B), NYHA (C), and age (D). ACP: advance care planning, HF: heart failure, SHFM: Seattle Heart Failure Model, NYAH: New York Heart Association functional classification.

**Figure S2.** Patients’ preferences of ACP conversations among five groups categorized according to age. ACP: advance care planning.

**Figure S3.** Patients’ preferences and actual performance of designating of a surrogate decision-maker and completing advance directives.

**Figure S4.** Bubble plot representation of the relationship between ACP preferences and EOL preferences. The horizontal axis shows the proportion of patients with positive attitudes towards ACP among those with positive attitudes towards each EOL component. The proportion of patients with positive attitudes towards each EOL component is represented through the size of the bubbles. ACP: advance care planning, EOL: end-of-life.
References

1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floy J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Paladini RN, Pandis PP, Parnianpour M, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Wong SS, Muntner P. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 2017; 135: e146-e603.

2. Kavaleratos D, Gellman LP, Tycon LE, Riegel B, Beekman DB, Ikejiani DZ, Goldstein N, Kimmel SE, Bakitas MA, Arnold RM. Palliative care in heart failure: rationale, evidence, and future priorities. J Am Coll Cardiol 2017; 70: 1919–1930.

3. Hollenberg SM, Warner Stevenson L, Ahmad T, Amin VJ, Bozkurt B, Butler J, Davis LL, Drazner MH, Kirkpatrick JN, Peterson FN, Reed BN, Roy CL, Storrow AB. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Foundation Committee on Practice Guidelines. J Am Coll Cardiol 2019; 74: 1966–2011.

4. Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med 2014; 28: 1000–1025.

5. Kernick LA, Hogg KJ, Millerick Y, Murtagh PEM, Djibaj A, Johnson M. Does advance care planning in addition to usual care reduce hospitalisation for patients with advanced heart failure: a systematic review and narrative synthesis. Palliat Med 2018; 32: 1539–1551.

6. Sobanski PZ, Alt-Epping B, Currow DC, Goodlin SJ, Grodzicki T, Hogg K, Janssen DJA, Johnson MJ, Krajnik M, Leget C, Martínez-Sellés M, Moroni M, Mueller PS, Ryder M, Simon ST, Stowe E, Larkin PJ. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiaco Res 2020; 116: 12–27.

7. Hill L, Prager Geller T, Barahou R, Beattie JM, Boysen J, de Stoutz N, Di Stolfi G, Lambrinou E, Skibilund AK, Uchmanowicz I, Rutten FH, Čelutičienė J, Piepoli MF, Jankowska EA, Chioncel O, Ben Gal T, Seferovic PM, Ruschitzka F, Coats AJS, Strömberg A, Jaarsma T. Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. Eur J Heart Fail 2020; 22: 2327–2339.

8. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, Komuro I, Saiyi Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiase A, Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama T, Murohara T, Momomura SL, Yono M, Yamazaki K, Yamamoto K, Yoshikawa T, Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki YK, Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T, Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kojima S, Kosuge M, Yamagishi M, Yamashina A. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version. Cir J 2019; 83: 2084–2184.

9. Young KA, Redfield MM, Strand J, Dunlay SM. End-of-life discussions in patients with heart failure. J Card Fail 2017; 23: 821–825.

10. Campbell RT, Petrie MC, McMurray JJV. Talking to patients with heart failure about end of life. Eur J Heart Fail 2018; 20: 1763–1765.

11. Nakamura K, Kinugasa Y, Sugihara S, Hirai M, Yanagihara K, Haruki N, Matsubara K, Kato M, Yamamoto K. Sex differences in surrogate decision-maker preferences for life-sustaining treatments of Japanese patients with heart failure. ESC Heart Failure 2018; 5: 1165–1172.

12. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA, American Heart Association Council on Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125: 1928–1952.

13. Stevenson LW, O’Donnell A. Advanced care planning: care to plan in advance. JACC Heart Fail 2015; 3: 122–126.

14. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–115.

15. Moriyama H, Kohno T, Kohsaka S, Shiraiishi Y, Fukuoka R, Nagatomo Y, Goda A, Mizuno A, Fukuda K, Yoshikawa T. Length of hospital stay and its impact on subsequent early readmission in patients with acute heart failure: a report from the WET-HF Registry. Heart Vessels 2019; 34: 1777–1788.

16. Kitakata H, Kohno T, Kohsaka S, Shiraiishi Y, Parizo JT, Niimi N, Goda A, Nishihata Y, Heidenreich PA, Yoshikawa T. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: a report from a Japanese multicenter registry. J Am Heart Assoc 2020; 9: e014949.

17. Shiraiishi Y, Kohsaka S, Nagai T, Goda A, Mizuno A, Nagatomo Y, Sujino Y, Fukuoka R, Savano M, Kohno T, Fukuda K, Anzai T, Shadman R, Dardas T, Levy WC, Yoshikawa T. Validation and recalibration of Seattle Heart Failure Model in Japanese acute heart failure patients. J Card Fail 2019; 25: 561–567.

18. Kitakata H, Kohno T, Kohsaka S, Fujisawa D, Nakano N, Shiraiishi Y, Katsumata Y, Yuasa S, Fukuda K. Prognostic understanding and preference for the communication process with physicians in hospitalized heart failure patients. J Card Fail 2021; 27: 318–326.

19. Dyer MTD, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010; 8: 13–13.

20. Jha MK, Qamar A, Vaduganathan M, Charnley DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2019; 73: 1827–1845.

21. Muramatsu K, Miyaoa K, Kamijima K, Muramatsu Y, Tanaka Y, Hosaka M, Miwa Y, Fuse K, Yoshimine F, Mashima I, Shimizu N, Ito H, Shimizu E. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry 2018; 52: 64–69.

22. Statement on treatment of elderly heart failure patients (the Japanese Heart Failure Society). http://www.ashs.or.jp/jhfs/pdf/StatementHeartFailure.pdf: Accessed 30 August 2021 (Japanese).

23. Hirai K, Miyashita M, Morita T, Sanjo M, Uchitomi Y. Good death in Japanese cancer care: a qualitative study. J Pain Symptom Manage 2006; 31: 140–147.

24. Miyashita M, Morita T, Sato K, Hirai K, Shima Y, Uchitomi Y. Good death inventory: a measure for evaluating good death from the bereaved family member's perspective. J Pain Symptom Manage 2008; 35: 486–496.

25. Miyashita M, Morita T, Sato K, Tsuneto S, Shima Y. A nationwide survey of quality of end-of-life cancer care in designated cancer centers, inpatient palliative care units, and home hospices in Japan: the J-HOPE study. J Pain Symptom Manage 2015; 50: 38–47e3.
26. Morita T, Chihara S, Kashiwagi T. A scale to measure satisfaction of bereaved family receiving inpatient palliative care. *Palliat Med* 2002; 16: 141–150.

27. Miyashita M, Sanjo M, Morita T, Hirai K, Uchitomi Y. Good death in cancer care: a nationwide quantitative study. *Ann Oncol Off J Eur Soc Med Oncol* 2007; 18: 1090–1097.

28. Waller A, Turon H, Bryant J, Zucca A, Evans TJ, Sanson-Fisher R. Medical oncology outpatients’ preferences and experiences with advanced care planning: a cross-sectional study. *BMC Cancer* 2019; 19: 63.

29. Ludmir J, Steiner JM, Wong HN, Kloosterboer A, Leong J, Aslakson RA. Palliative care opportunities among adults with congenital heart disease—a systematic review. *J Pain Symptom Manage* 2019; 58: 891–898.

30. Johnson S, Butow P, Kerridge I, Tattersall M. Advance care planning for cancer patients: a systematic review of perceptions and experiences of patients, families, and healthcare providers. *Psychooncology* 2016; 25: 362–386.

31. Bernacki R, Paladino J, Neville BA, Hutchings M, Kavanagh J, Geerse OP, Lakin J, Sanders JJ, Miller K, Lipsitz S, Gawande AA, Block SD. Effect of the serious illness care program in outpatient oncology: a cluster randomized clinical trial. *JAMA Intern Med* 2019; 179: 751–759.

32. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *BMJ* 2010; 340: c1345.

33. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tusky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 2000; 284: 2476–2482.

34. Ek K, Ternestedt BM. Living with chronic obstructive pulmonary disease at the end of life: a phenomenological study. *J Adv Nurs* 2008; 62: 470–478.

35. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR,侯jola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Rutten LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.

36. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *BMJ* 2010; 340: c1345.

37. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tusky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 2000; 284: 2476–2482.

38. Ek K, Ternestedt BM. Living with chronic obstructive pulmonary disease at the end of life: a phenomenological study. *J Adv Nurs* 2008; 62: 470–478.

39. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Rutten LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.

36. Auriemma CL, Nguyen CA, Bronheim R, Kent S, Nadiger S, Parido D, Halpern SD. Stability of end-of-life preferences: a systematic review of the evidence. *JAMA Intern Med* 2014; 174: 1085–1092.

37. Chuze S, Khan SS, Pak ES. Primary palliative care education in advanced heart failure and transplantation cardiology fellowships. *J Am Coll Cardiol* 2021; 77: 501–505.

38. Halpern SD. Goal-concordant care—searching for the holy grail. *N Engl J Med* 2019; 381: 1603–1606.

39. Flint LA, David DJ, Smith AK. Rehabbed to death. *N Engl J Med* 2019; 380: 408–409.